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ABSTRACT

for intranasal administration to a mammal that contain an

effective amount of an opioid, a liquid nasal carrier for the

opioid, and optionally a sweetener, ?avoring agent or mask
ing agent. In some embodiments of the present invention, the

pharmaceutical compositions have improved bioavailability.
In other embodiments of the present invention, the opioid

compositions improve patient compliance.
12 Claims, 5 Drawing Sheets
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INTRANASAL OPIOID COMPOSITIONS

alleviating the symptoms of colds and allergies that they or a
family member have used routinely. Another important con
sideration is that the patient can self-administer the pre
scribed dosage(s) of nasal spray Without the need for trained

This application is a continuation of US. application Ser.
No. 11/674,803, ?led Feb. 14, 2007 noW abandoned, Which is
a continuation of US. application Ser. No. 10/647,789, ?led
Aug. 25, 2003 noW abandoned, Which is a continuation-in

medical personnel.

part of US. application Ser. No. 09/790,199 ?led Feb. 20,

ids (e.g., morphine, methadone, hydromorphone, butorpha

2001 now US. Pat. No. 6,610,271, Which is a continuation

nol, etc.) play one of the most important roles. The major
advantage of the opioids is that they have an extensive history

Among the many medications available to treat pain, opio

in-part ofU.S. application Ser. No. 09/569, 125 ?led May 10,
2000, noW abandoned. The entire disclosure of these appli

of use and are much more effective in treating severe pain than

cations is herein incorporated by reference.

other classes of medications e.g. aspirin, acetaminophen, ibu
profen, etc. Another major advantage is that opioids exhibit

BACKGROUND OF THE INVENTION

feW adverse effects on organs such as the stomach, liver, or
kidney, other than very minor problems such as nausea or
constipation. This is a major bene?t over other medications
such as aspirin or anti-in?ammatory drugs that may cause

Pain is a major symptom of many diseases, (e.g., cancer,

arthritis, neurological diseases, heart attacks, etc.). Inad
equate treatment of pain can lead to depression, anger, fear of
disease progression and in some extreme cases, suicide.
Unfortunately, a patient’s non-compliance or failure to
take medication as prescribed, has been linked to inadequate

ulcers, kidney problems, high blood pressure, or liver in?am
mation. In addition to relieving pain, opioids have other ben
e?cial effects, such as, for example, peripheral arterial
20

treatment of pain. This is not surprising, since many pain

vasodilation, When treating heart attacks, provides the bene?t
of reducing oxygen demand on the heart.
There are different intranasal opioid formulations knoWn

treatment regimens involve administering pain medications
by injection route (e. g., intravenous (IV), intramuscular (IM)
pain medication to achieve rapid pain relief. Intravenous

in the pharmaceutical arts. HoWever, some intranasal opioid
formulations have reduced bioavailability at conventional
doses. These formulations require more pain medication to be
administered to the patient or else the pain Will be inad

administration may cause non-compliance, because not only

equately treated.

do patients fear getting the injection, but unpleasant experi

Given the problems associated With inadequate treatment
of pain and patient noncompliance, there is a need for intra

or subcutaneous injection). The intravenous route is normally
regarded as one of the most in-convenient routes to administer

25

ences such as pain, irritation and infection resulting at the

injection site may also lead to non-compliance.

30

The intranasal route is currently receiving special interest,
especially in the area of pain management. When medication
is administered via the intranasal route, the medication is
applied to the nasal mucosa Where it is absorbed. The exten
sive netWork of blood capillaries under the nasal mucosa is

There is also a need for intranasal compositions that improve

patient compliance.
SUMMARY OF THE INVENTION
35

particularly suited to provide rapid and effective systemic

In various embodiments, the present invention provides
intranasal opioid compositions that have improved bioavail
ability When compared to intranasal prior art opioid compo
sitions. In other embodiments, the present invention provides

absorption of drugs. The intranasal route of administration
should achieve similar dose to plasma concentration (bio
availability) and e?icacy to that of the intravenous route.
Intranasal administration of medication provides numer
ous advantages over the intravenous route. The principal

40

In one embodiment, the present invention provides a phar

45

maceutical composition for intranasal administration to a
mammal; comprising: an effective amount of an opioid; a
liquid nasal carrier for the opioid; and one or more sWeeten
ers, ?avoring agents, or masking agents or combinations
thereof.

In another embodiment, the present invention provides a

pharmaceutical composition having improved bioavailability

syringes have also been imposed.
In contrast, intranasal administration requires little time on

intranasal opioid compositions that improve patient compli
ance.

advantages of intranasal route are non-invasive delivery, rapid
drug absorption, and convenience. The intravenous route,
unlike the intranasal route, requires steriliZation of hypoder
mic syringes and, in the institutional setting, leads to concerns
among medical personnel about the risk of contracting dis
ease if they are accidentally stuck by a contaminated needle.
Strict requirements for the safe disposal of needles and

nasal opioid compositions that have improved bioavailability.

50

for intranasal administration to a mammal; comprising: an

the part of the patient and attending medical personnel, and is

effective amount of butorphanol; a preservative-free liquid

far less burdensome on the institution than injectable routes.
There is no signi?cant risk of infection of the patient or

nasal carrier.

medical personnel in the institutional setting When dealing

a pharmaceutical composition having improved bioavailabil

With the intranasal delivery of medication.
A second important advantage of intranasal administration
over intravenous is patient acceptance of the intranasal deliv

In still another embodiment, the present invention provides
55

ery route. In some cases, the injections cause burning edema,

sWelling, turgidity, hardness and soreness. In contrast, intra
nasal administration is perceived as non-invasive, is not

masking agent.
60

accompanied by pain, has no after-effects and produces
prompt relief in the patient exhibiting pain symptoms. This is
of particular advantage When the patient is a child. Many, if
not most, patients experience anxiety and exhibit symptoms
of stress When faced With hypodermic injections via the IM or
IV routes. Further, most people have some familiarity With
nasal sprays in the form of over-the-counter decongestants for

ity for intranasal administration to a mammal; comprising: an
effective amount of hydromorphone; a liquid nasal carrier
having the essential absence of a preservative and the com
position containing at least one sWeetener, ?avoring agent or

In one preferred embodiment, the present invention pro
vides a pharmaceutical composition for intranasal adminis
tration to a mammal; comprising: an effective amount of

hydromorphone; a preservative-free liquid nasal carrier com
prising sodium chloride, citric acid, Water and at least one
65

sWeetener, ?avoring agent or masking agent.
In still another preferred embodiment, the present inven
tion provides a method of treating a mammal suffering from

US 8,198,291 B2
pain comprising intranasally administering to the mammal an

4
apomorphine, hydromorphone, oxymorphone, dihydromor

effective amount of butorphanol or hydromorphone; a preser

phine, levorphanol, levallorphan, levophenacylmorphan, nor

vative-free liquid nasal carrier comprising sodium chloride,

levorphanol, nalorphine, nalbuphine, buprenorphine, butor
phanol, naloxone, naltrexone, nalmexone, oxilorphan,
cyclorphan, ketobemidone, fentanyl, sufentanil, alfentanyl,

3

citric acid, Water and at least one sWeetener, ?avoring agent or

masking agent.

or combinations thereof. The most preferred opioids for use

For a better understanding of the present invention together
With other and further advantages and embodiments, refer
ence is made to the following description taken in conjunction

in the present invention include butorphanol and/or hydro

morphone.
The opioid may be in free form or in pharmaceutically

With the examples, the scope of Which is set forth in the

acceptable salt or complex form. Some examples of pharma
ceutically acceptable salts of opioids include those salt-form
ing acids and bases that do not substantially increase the
toxicity of the compound. Some examples of suitable salts

appended claims.
BRIEF DESCRIPTION OF THE FIGURES

include salts of alkali metals such as magnesium, potassium
and ammonium. Salts of mineral acids such as hydrochloric,

Preferred embodiments of the invention have been chosen
for purposes of illustration and description, but are not
intended in any Way to restrict the scope of the invention. The
preferred embodiments of certain aspects of the invention are

hydriodic, hydrobromic, phosphoric, metaphosphoric, nitric

shoWn in the accompanying ?gures, Wherein:

tartaric, acetic, citric, malic, benZoic, glycollic, gluconic,
gulonic, succinic, arylsulfonic, e.g. p-toluenesulfonic acids,

FIG. 1 is a graphic representation of the concentration of
butorphanol in blood plasma versus time after administration

and sulfuric acids, as Well as salts of organic acids such as

20

and the like.

25

include a liquid nasal carrier. As used herein, “liquid nasal
carrier” includes a solution, emulsion, or suspension
designed for delivery of the opioid to the nasal mucosa. The
liquid nasal carrier includes a diluent suitable for application

Intranasal opioid compositions of the present invention

of the test formulation from a unit-dose spray device (Inven
tion)) and the administration of the test formulation in a

multi-dose spray device (Prior Art).
FIG. 2 is a graphic representation of the data of FIG. 1 over

a longer time period.
FIG. 3 is a graphic representation of the concentration of
hydromorphone in blood plasma versus time for IV, IM and

to the nasal mucosa. Suitable diluents include aqueous or

non-aqueous diluents or combination thereof. Examples of
aqueous diluents include, but are not limited to, saline, Water,
dextrose or combinations thereof. Non-aqueous diluents

intranasal (IN) doses (mean (n:9) Hydromorphone concen
tration versus time graphs folloWing IV, IM, and IN doses of
2 mg Hydromorphone HCI (6 hrs after dose).

30

a longer period of time (mean (n:9) Hydromorphone concen
tration versus time graphs folloWing IV, IM, and IN doses of
2 mg Hydromorphone HCI (16 hrs after dose).
FIG. 5 is a graphic representation of the concentration of

include, but are not limited to, alcohols, particularly polyhy

droxy alcohols such as propylene glycol, polyethylene gly
col, glycerol, and vegetable and mineral oils. These aqueous

FIG. 4 is a graphic representation of the data of FIG. 3 over

and/or non-aqueous diluents can be added in various concen

trations and combinations to form solutions, suspensions,
35

oil-in-Water emulsions or Water-in-oil emulsions. In the pre

hydromorphone in blood plasma versus time for a group of

ferred butorphanol or hydromorphone compositions, the

subjects (graph of Hydromorphone concentrations versus

diluent is saline or Water.

The nasal carrier of the present invention may also contain

time folloWing IN doses of 2 mg Hydromorphone HCI to 9

subjects.
40

Antioxidants are substances that prevent oxidation of the
formulations. Suitable antioxidants for use in the present

DETAILED DESCRIPTION OF THE INVENTION

invention include, but are not limited to, butylated hydroxy

The invention Will noW be described in connection With

toluene, butylated hydroxyanisole, potassium metabisul?te,

preferred embodiments. These embodiments are presented to
aid in an understanding of the present invention and are not
intended to, and should not be construed to, limit the inven

excipients such as antioxidants, chemical preservatives, buff
ering agents, surfactants and/or agents that increase viscosity.

45

and the like.
In some embodiments of the present invention, the com

tion in any Way. All alternatives, modi?cations and equiva

position contains a preservative that is chosen in quantities

lents that may become obvious to those of ordinary skill on
reading the disclosure are included Within the spirit and scope

that preserve the composition, but do not cause irritation of

of the present invention.

the nasal mucosa. Suitable preservatives for use in some
50

tion, it has noW been surprisingly found that intranasal phar
maceutical compositions can be made having improved bio
availability in terms of plasma opioid levels. These intranasal
compositions contain an opioid; and a liquid nasal carrier for

butylparaben, benZyl alcohol, phenylethyl alcohol, benZetho
55

the opioid. For example, it has been unexpectedly discovered,

In some embodiments of the present invention, the formu

ing an intranasal formulation from a unit-dose spray device.
60

opioid formulations. Preferred increases include, but are not
limited to, increases of more than 5% to 40% in bioavailabil

ity of the opioid.
Opioids as herein include any substance naturally or syn

thetically derived from opium. Suitable opioids for use in the
present invention include, but are not limited to, morphine,

nium, or combination thereof. Typically, the preservative is
added to the compositions of the present invention in quanti
ties of from about 0.01% to about 0.5% by Weight.

lation is preservative-free. As used herein, preservative-free

among other things, that at least about 10 to about 20% higher
plasma levels of butorphanol can be achieved by administer

Improved bioavailability includes increases in plasma or
serum opioid concentration When compared to prior art

embodiments of the present invention include, but are not

limited to, benZalkonium chloride, methyl, ethyl, propyl or

In accordance With one embodiment of the present inven

65

includes compositions that do not contain any preservative.
Thus, the composition does not contain, for example, benZa
lkonium chloride, methyl, ethyl, propyl or butylparaben, ben
Zyl alcohol, phenylethyl alcohol, or benZethonium.
If a buffering agent is employed in the composition, it is
chosen in quantities that preferably do not irritate the nasal
mucosa. Buffering agents include agents that reduce pH
changes. Preferred buffering agents for use in the present
invention include, but are not limited to, salts of citrate,
acetate, or phosphate. The most preferred buffers include

US 8,198,291 B2
5

6

sodium citrate, sodium acetate, sodium phosphate, and/or

dextrose, glycosides, maltose, sWeet orange oil, dextrose,

combinations thereof. Typically, the buffer is added to the

glucose, honey or combinations thereof. Most preferred ?a

compositions of the present invention in quantities of from
about 0.01% to about 3% by Weight.

voring agents to use in some embodiments of the present
invention include, but are not limited to, glycerin, Winter

When one or more surfactants is employed, the amount

green oil, peppermint oil, peppermint Water, peppermint

present in the compositions of the invention Will vary depend
ing on the particular surfactant chosen, the particular mode of
administration (e.g. drop or spray) and the effect desired. In
general, hoWever, the amount present Will be of the order of
from about 0.1 mg/ml to about 10 mg/ml, preferably about 0.5
mg/ml to 5 mg/ml and most preferably about 1 mg/ml.
The pharmaceutical compositions of the present invention

spirit, menthol, syrup, or combinations thereof. Most pre
ferred masking agents do not make contact With the taste

buds. The preferred masking agent for use in the present
invention includes, but is not limited to, cyclodextrins, cyclo

dextrins emulsions, cyclodextrins particles, cyclodextrins
complexes, or combinations thereof.

The pharmaceutical compositions of different embodi

may include one or more agents that increase viscosity cho

ments of the present invention may of course also include

sen in quantities that preferably do not irritate the nasal
mucosa and increase nasal retention time. Preferred agents
that increase viscosity include, but are not limited to, meth

additional ingredients, such as pharmaceutically acceptable

surfactants, co-solvents, adhesives, agents to adjust the pH
and osmolarity.
The pharmaceutical compositions of the present invention

ylcellulose, carboxymethylcellulose sodium, ethylcellulose,
carrageenan, carbopol, and/or combinations thereof. The
most preferred agents used to increase viscosity and increase
nasal retention time is methylcellulose or carbopol. Typically,
the agent that increases viscosity is added to the compositions
of the present invention in quantities of from about 0.1% to

20

ranges are from about 4 to about 5. If the adjustment of the pH
is needed, it can be achieved by the addition of an appropriate
acid, such as hydrochloric acid, or base, such as for example,

about 10% by Weight.
In some embodiments of the present invention, one or more
sWeetener or ?avoring agents are employed. The sWeetener or

25

?avoring agent includes any agent that sWeetens or provides
?avor to the pharmaceutical composition: The sWeetener or

occur if the pharmaceutical composition drips back into the

the present invention can be made, for example, by mixing the
30

opioid With a liquid nasal carrier and/or a sWeetener, ?avoring

35

temperature under aseptic conditions to form a mixture. In
other embodiments of the present invention, the mixture is
?ltered. It Will be understood by those of ordinary skill in the
art that the order of mixing is not critical, and the present
invention includes Without limitation mixing of the formula
tion in any order.
Pharmaceutical compositions of the present invention can

agent, or masking agent or combinations thereof at room

position because of unpleasant taste is reduced. By adding a
sWeetener, ?avoring agent or masking agent to the intranasal

pharmaceutical composition of the present invention, patient
compliance is enhanced or improved.
Preferred sWeeteners or ?avoring agents or masking agents
to use in some embodiments of the present invention include,
but are not limited to, acacia syrup, anethole, anise oil, aro

matic elixir, benZaldehyde, benZaldehyde elixir, cyclodex

sodium hydroxide. In the preferred embodiments of the
present invention, butorphanol or hydromorphone formula
tions, have a pH of about 5 .0 and a pH of about 4, respectively.
The pharmaceutical composition in some embodiments of

?avoring agent Will mask any bitter or bad taste that may
mouth after intranasal administration. By addition of a sWeet
ener or ?avoring agent to the intranasal composition, any
barrier that a patient may have to taking the intranasal com

are not limited to any particular pH. HoWever, generally for
nasal administration a mildly acid pH Will be preferred. The
pH ranges from about 3 to 6 are preferred, more preferred pH
ranges are from about 3 to about 5, and most preferred pH

40

be administered intranasally by nasal spray, drop, solution,
suspension, gel, and the like. In one preferred embodiment,

trins, compound, caraWay, caraWay oil, cardamom oil, carda
mom seed, cardamom spirit, compound, cardamom tincture,

the pharmaceutical composition of the present invention is a

compound, cherry juice, cherry syrup, cinnamon, cinnamon

When the pharmaceutical composition is a liquid, pre
ferred volumes of the liquid are absorbed through the nasal
mucosa. The preferred volume of the liquid includes volumes
of from about 0.025 ml to about 2 ml, more preferably, from
about 0.25 ml to 1 ml, and most preferably from about 0.05 ml

oil, cinnamon Water, citric acid, citric acid syrup, clove oil,
cocoa, cocoa syrup, coriander oil, dextrose, eriodictyon, eri

sterile solution or suspension.

45

odictyon ?uidextract, eriodictyon syrup, aromatic, ethylac
etate, ethyl vanillin, fennel oil, ginger, ginger ?uidextract,
ginger oleoresin, dextrose, glucose, sugar, maltodextrin,
glycerin, glycyrrhiZa, glycyrrhiZa elixir, glycyrrhiZa extract,
glycyrrhiZa extract pure, glycyrrhiZa ?uidextract, glycyrrhiZa
syrup, honey, iso-alcoholic elixir, lavender oil, lemon oil,
lemon tincture, mannitol, methyl salicylate, nutmeg oil,
orange bitter, elixir, orange bitter, oil, orange ?oWer oil,

to about 15 ml in an adult and smaller for children. HoWever,

the pharmaceutical compositions of the present invention are
50

Preferred devices for intranasal delivery of pharmaceutical
compositions of the present invention are available from, for
example, Pfeiffer of America of Princeton, N]. and Valois of
America, Inc. of GreenWich, Conn. These devices are pre

orange ?oWer Water, orange oil, orange peel, bitter, orange

peel sWeet, tincture, orange spirit, compound, orange syrup,

not limited to one particular volume.

55

ferred because they have the capability of consistently deliv

peppermint, peppermint oil, peppermint spirit, peppermint

ering the pharmaceutical composition. These devices are eas

Water, phenylethyl alcohol, raspberry juice, raspberry syrup,

ily operable by the patient, leave virtually no opioid

rosemary oil, rose oil, rose Water, rose Water, stronger, sac

remaining in the device after use and can thereafter be dis
carded Without concern that others may abuse the opioid or
other controlled substance.
The device can be ?lled With single or multidose amounts

charin, saccharin calcium, saccharin sodium, sarsaparilla
syrup, sarsaparilla compound, sorbitol solution, spearmint,
spearmint oil, sucrose, sucralose, syrup, thyme oil, tolu bal

60

of opioids. Preferably, the device is ?lled With one single dose
of opioid. In a preferred embodiment, the container holding

sam, tolu balsam syrup, vanilla, vanilla tincture, vanillin, Wild
cherry syrup, or combinations thereof.
Most preferred sWeeteners to use in some embodiments of

the present invention include, but are not limited to, saccha

rin, sodium saccharin, xylitol, mannitol, sorbitol, sucralose,
maltodextrin, sucrose, aspartame, acesulfame potassium,

65

the pharmaceutical composition and its sealing means are
steriliZable, most preferably, at least parts of the device that
are in contact With the pharmaceutical composition is con
structed and assembled in a con?guration that can be steril

US 8,198,291 B2
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iZed. Devices With one or more unit-dose(s) can be sterilized

administer 0.1 ml of liquid composition by metering upon

either before or after packaging, employing methods and

activation by the user. The formulation had the folloWing
function and properties When administered to human subjects

technology that are Well knoWn in the art. Individual devices

can be packaged, steriliZed and shipped; alternatively, entire

via the Pfeiffer Unitdose Second Generation spray device.
Administration of a 2 mg dose of butorphanol tartrate pro
duced a Tmax (hr) of about 0.234 (range about 0.083 to about

shipping and storage packages can be steriliZed at once, and

the devices removed individually for dispensing, Without
affecting the sterility of the remaining units.

0.333); a Cmax (pg/ml) of about 5230 (range ofabout 2393 to
about 8478); an AUC(O_t) of about 10661 pg*hr/ml (range of
about 5351 to about 17722). Administration using the multi

The amount of opioid that can be intranasally administered
in accordance With the composition and methods of the

present invention Will depend on the particular opioid chosen,

dose spray pump produced a Tmax of 0.245 hr, a Cmax of 4072
pg/ml and an AUC(O_t) of 9329 pg*hr/ml.
The second delivery system employed to administer the
butorphanol compositions Was a unit-dose disposable intra
nasal applicator that is commercially available from Pfeiffer
of America under the designation “Unitdose Second Genera

the condition to be treated, the desired frequency of admin
istration and the effect desired. As used herein, an effective
amount of opioid includes that amount effective to achieve
the relief or palliation of symptoms, condition and/ or diseases
associated With pain. Some diseases and/or conditions that
cause pain include, but are not limited to, cancer, arthritis,

neurological diseases, heart attacks, trauma, childbirth,
migraines, or surgery.

Maximal dosage of the pharmaceutical composition of the
present invention for a mammal is the highest dosage that

20

elicits analgesia or anesthesia, Which does not cause undesir
able or intolerable side effects such as respiratory depression.

The minimal dose of the opioid is the loWest dose that
achieves the desired result. In any event, the practitioner is

guided by skill and knoWledge in the ?eld, and the present

25

invention includes Without limitation dosages that are effec
tive to achieve the pain relieving effect in the mammal. Pre

tion.” Each of the Pfeiffer spray applicators Was charged With
suf?cient liquid to deliver a 0.1 mL dose of the butorphanol
test formulation. The glass containers Were ?lled using a
pipette under clean conditions, sealed and assembled to the
applicator. Each of the applicators Was Weighed prior to use
and after use. Quali?ed medical personnel administered, one
dose into each nostril, after Which the applicator Was recov
ered for Weighing. In the case of the unit-dose applicators
(test formulation), tWo devices Were used for each patient,
both of Which Were discarded folloWing the post-use Weigh
ing. The results of these studies of the method and system of
the invention and the comparative prior art method folloW.

ferred doses of opioids for intranasal administration include,
but are not limited to, hydromorphone HCL from about 0.1
mg to about 30 mg; butorphanol tartrate from about 0.1 to
about 10.0 mg; fentanyl citrate from about 5 mcg to about 500
mcg; methadone HCl from about 0.5 to about 50 mg; oxy
morphone HCL from about 0.1 mg to about 30 mg; and
morphine HCL from about 1 mg to about 40 mg.

The intranasal opioids of the present invention can be used,
for example, to elicit analgesia or an analgesic response to
relieve or alleviate pain. The opioids of the present invention

TABLE I
30

Sample Characteristics of Dose Weight Delivery.
Delivery
System
35 Unit-Dose
Multi-Dose

mean Wt.
gms

23
24

0.206
0.180

std.
dev.

std.
error

0.00660 0.00138
0.0285 0.00582

minimum

maximum

0.193
0.114

0.223
0.220

Unit-Do se:

may also be used to produce anesthesia or an anesthetic

response Where the mammal experiences loss of feeling or

sensation, especially loss in pain sensation, to permit the

N
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performance of surgery or other painful procedures. The
opioid is administered to a mammal suffering from a condi

The statistical comparison of dose 1 and dose 2 for the test
formulation unit dose delivery system Was done using a
paired t-test. Analysis of the data indicated that the difference
betWeen the mean, sprays of the tWo applications using the

tion and/or disease that require opioid treatment. Mammals

Pfeiffer device Was not statistically signi?cant (t:1.0; p:0.3).

include, for example, humans, as Well as pet animals such as

The sample of 23 sprayers (actually 23 sets of 2 sprayers,

dogs and cats, laboratory animals, such as rats and mice, and

since they Were single-dose) had a mean total dose for tWo
sprays of 0.206 grams With a standard deviation of 0.00660
grams.

farm animals, such as horses and coWs.

Multiple-Dose:

EXAMPLES

The total dose dispensed by tWo sprays Was recorded. The

The examples beloW demonstrate improved bioavailability

50

of illustrative compositions of the present invention When
delivered from a unit-dose spray device compared to the same
compositions When delivered from a multi-do se spray device.

Comparison of Average Total Dose:

The examples also shoW pharmaceutical compositions that
include sWeeteners, ?avoring agents, or masking agents or

55

ance.

Example 1
60

signi?cantly closer to the prescribed target and dose than the
multi-dose mean total dose (t:4.3; p<0.001). A 95% con?
dence interval for the difference in means is (0.0140, 0.03 80).

Comparison of Variability:

This example compares bioavailability of a butorphanol

The F test for the comparison of variances revealed that the

formulation When administered using a unit-dose or multi

sodium hydroxide and hydrochloric acid added to adjust the
pH to 5.0. The multi-dose sprayer purports by its label to

The tWo-sample t-test for the comparison of the unit-dose
and multi-dose sprayers indicated a statistically signi?cant
difference betWeen the mean total doses taking into account
the siZe of the sample. The unit-dose mean total dose Was

combinations thereof, Which can improve patient compli

dose delivery device. The formulation contains 10 mg butor
phanol tartrate, 6.5 mg sodium chloride, 1.0 mg citric acid,
0.20 mg benZethonium chloride in puri?ed Water With 1 .2 mg

sample of 24 multi-dose sprayers had a mean total dose for
tWo sprays of 0. 1 80 grams With a standard deviation of 0.0285
grams.

variability in the total doses dispensed by the multi-dose
sprayer Was signi?cantly higher than the variability in
65

Weights dispensed by the unit-dose sprayer (13:18.7;
p<0.001). The variability in the multi-dose sprayer is 18.6
times that of the unit-dose sprayer. High variability in dose

US 8,198,291 B2
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delivery leads to higher rates of adverse drug effects at exces
sive dose and inadequate treatment if the dose is loW. Both

TABLE 2

consequences harm the patient hence the goal is to precisely
deliver the prescribed dose.
Comparison of Each Sprayer to the Standard of 0.2 Grams

Summag of the tWo one-sided hypothesis tests for PK parameters

Parameter

Lower Conf Limit for
Ratio of Test/Reference

Upper Conf Limit for
Ratio of Test/Reference

A t-test Was used in each case to compare the observed

sample mean to the desired Weight of 0.2 grams. The unit
dose sprayer dispensed a mean total Weight that Was signi?

Tmax

0.749

1.132

cantly higher than the goal of 0.2 grams (t:4.4; p<0.001). A

log (Cmax)*
log (AUClast)*

1.031
1.037

1.855
1.540

log(AUCinf)*
log(normCmax)*
log(AUClast)*
log(normAUCinf)*

1.050
0.897
0.921
0.937

1.461
1.5 89
1.290
1.220

95% con?dence interval for the mean total Weight dispensed

by the unit-dose sprayer is (0.203, 0.209). The multi-dose
sprayer dispensed a mean total Weight that Was signi?cantly

loWer than the goal of 0.2 grams (t:3.4; p<0.003). A 95%
con?dence interval for the mean total Weight dispensed by the
multi-dose sprayer is (0.168, 0.192). Based on the above, the

*Note:
The actual con?dence limits obtained for these parameters have been exponentiated since
the data Were log-transformed originally.

unit-dose delivery system of the test formulation exhibits a

Since none of these con?dence intervals for the non-stan
dardized data are contained in the interval from 0.8 to 1.25,
the conclusion is that the tWo (test and reference) are not
equivalent When compared on raW values. For Tmax, the one

much higher degree of accuracy in intranasally administering
the volume of liquid composition corresponding to 0.1 gm:
+3% vs —10%.

Bioequivalence

20

This example assesses the bioequivalence of a butorphanol
formulation administered from the unit-dose or multi-dose

sprayers described above. The test formulation comprises 1
ml of STADOL NS containing 10 mg butorphanol tartrate,
6.5 mg sodium chloride, 1.0 mg citric acid, 0.20 mg benze
thonium chloride in puri?ed Water With 1.2 mg sodium
hydroxide and hydrochloric acid added to adjust the pH to
5 .0. The multi-dose sprayer accompanying STADOL NS pur
ports, by its label, to administer 0.1 ml of liquid. The unit
dose delivery device delivers 0.1 ml of liquid.

by dispensed doses does improve the comparability of the tWo
devices, tWo of the three parameters fail to reject the null
25

30

years unexpectedly delivers beloW label strength. The degree
of variability is also signi?cantly greater than that of the
method of the invention using the Pfeiffer device. Since the
35

considers both raW and normalized data, With the latter stan

test formulation administered from the unit-dose device
achieves higher drug serum concentration, the small excess in

unit-dose administration can be further reduced by adjusting

40

sequence (4 levels), period 3 levels) and formulation (2 lev

the volume and/or drug concentration placed in the delivery
device. Thus, the drug container can actually be ?lled With
less drug.
Equality of Variances
The Pitman-Morgan adjusted F test Was used to compare

variances of the unit-dose and multi-dose parameters. (See

els) Were included in the model. Additionally, gender, as Well
as the interactions betWeen gender and each of sequence,
period and formulation Was included as a factor in each model

The data shoW that the FDA-approved (STADOL NS)
product that has been sold and dispensed for a number of

subject variabilities of the tWo spray devices are equal. The
study Was initiated With 16 subjects, 15 of Which completed
the study to provide data for this analysis; one subject
dardized With respect to the dose dispensed.
For both the raW and normalized data, log transformations
are applied to the pharmacokinetic endpoints Cmax, AUC
(00891 ast), and AUC(inf.). A mixed effects model Was con
sidered for each parameter. Fixed effects for the factors

hypothesis HO: Test/Reference >1 .25. Bioequivalence is sup
ported only by the pair of one-sided tests for the normalized,
log-transformed AUC(inf). Both one-sided t-test for each of
the seven parameters have been performed at an alpha level of
0.05.

The second analysis Was to determine Whether the intra

dropped out after the second period. The folloWing analysis

sided t-test for H0: Test/ Reference <0.8 is not rejected. Also,
the tests of HO: Test/Reference >1.25 are not rejected for any
of the log-transformed raW values. While the normalization

45

ChoW, S-C. and Liu, J-P, Design and Analysis ofBioavail
ability and Bioequivalence Studies. Marcel Dekker, Inc.,

to determine Whether separate analyses Would be necessary

NeW York (2000)). Since this test could not be generalized to

for males and females. A total of seven models Were consid

the three period design, the ?rst tWo periods of the butorpha

ered: Tmax, log of raW Cmax values, log of normalized Cmax
values, log transformed values for raW and normalized AUC
(last), and log values for raW and normalized AUC(inf.). In all
cases, the interaction betWeen gender and formulation Was

50

not signi?cant, indicating that separate models for males and

nol trial Were used, and for the purposes of this analysis, there
are tWo delivery systems, tWo periods, and tWo sequences.
The Pitman-Morgan adjusted F test can be used even if the
period effect is signi?cant, and has a simpli?ed form in the
absence of period effects. Of the seven PK parameters con

females Were not Warranted. In addition, the lack of signi?
cance of the effects included in each model indicate that there
Was no evidence of unequal carryover betWeen the delivery
system of the prior art and that in one embodiment of the

55

3 summarizes the results of the tests of equality. The null
hypothesis is that the variances are equal, and small p-values
are indicative of a departure from equality.

sidered, only Tmax exhibited a signi?cant period effect. Table

present invention.
The mean levels of butorphanol from analysis of the sub
ject’ s blood plasma reported in pg/ml are plotted against time
in FIGS. 1 and 2. The concentration of drug for the unit-dose
Was unexpectedly higher than that of the multi-dose system.
The testing for bioequivalence Was done using the method of
tWo one-sided t-test (as described by Bolton, S., Pharmaceu
tical Statistics. Marcel Dekker, Inc., NeW York, 1997, pages
415 ff.). For each parameter, the 90% con?dence interval for
the ratio of the test unit-dose to reference multi-dose devices
appear in Table 2 beloW.

TABLE 3
60

Summag of the Pitman-Morgan’s ad'usted F tests for PK parameters

Parameter
Tmax

65

log
log
log
log

(Cmax)
(AUClast)
(AUCinf)
(normCmax)

Pitman-Morgan P Value
0.3

11.3
30.1
15.3
8.4

p-value
0.6

0.005
<0.0001
0.002
0.01
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TABLE 3-continued

about 93.88 pm (range of 69.55 to 117.15). The spray had a
mean span [(Dv90-Dv10/Dv50)] of about 1.76 (range of

Summag of the Pitman-Morgan’s ad'usted F tests for PK parameters

1.55-1.91).

Parameter

At a spray distance of 3 cm, the spray had a droplet siZe
distribution having a mean Dv10 of about 13.83 pm (range of
11.84 to 15.68), a mean Dv50 of about 35.29 pm (range of
29.46 to 41.69) and a mean Dv90 ofabout 90.80 pm (range of
71.2 to 122.42). The spray had a mean span [(Dv90-Dv10/

log (AUClast)
log (nonnAUCinf)

Pitman-Morgan P Value

p-value

23.7
10.7

0.0002
0.0005

Dv50)] of about 2.17 (range of 1.92-2.56).

The tests of equality variances indicate that for all PK
parameters except Tmax, the variabilities of the two dose
systems are signi?cantly different, with the unit dose system

At a spray distance of 5 cm, the spray had a droplet siZe
distribution having a mean Dv10 of about 15.82 pm (range of
14.38 to 17.17), a mean Dv50 of about 32.96 pm (range of
31.03 to 35.32) and a mean Dv90 ofabout71.85 um (range of
61.64 to 83.68). The spray had a mean span [(Dv90-Dv10/

demonstrating much lower variability of drug levels in the
blood. While the normalization of the Cm“, AUC(last) and
AUC(inf) parameters somewhat decreased the difference
between the variances (as evidenced by slightly smaller F
values), the variances were nonetheless signi?cantly differ

Dv50)] of about 1.69 (range of 1.50-1.90).
The formulation had the following function and properties
when administered to human subjects via the Pfeiffer Unit

ent. The variability associated with the unit-dose system was

smaller than that of the multi-dose system of the prior art,
which is consistent with the ?ndings of the delivery volume

weight study.

dose Second Generation spray device. Administration of a
20

single 2 mg dose of butorphanol tartrate produced a Tmax (hr)
ofabout 0.25 (range of0.167 to about 0.5); a Cmax (ng/ml) of
about 2.08 to about 4.68; and an AUC(O_t) of about 7.6 to

From the above, it is apparent that the dose wei ght/volume
data is con?rmed by the blood level (pharmacokinetic) analy

about 11.41 ng*hr/ml.

sis. The formulation administered from the multi-dose device

Example 2

results in an area under the curve that is 90% of the test 25

formulation of the present invention. Thus, the test device
achieves 10% higher area under the curve and 10% higher

Hydromorphone lntranasal Solution

serum levels as compared to the reference device. This dif

ods are applied, it is concluded thatithe products as

In accordance with the composition and methods described
above, hydromorphone HCL (HM HCL) was formulated in a
liquid composition for use in the practice of one embodiment
of the invention. HM HCL is a potent mu-receptor agonist

administered to the patients are not equivalent. Thus, the

opiate analgesic with properties similar to morphine. HM

unit-dose device in one embodiment of the present invention

HCL is chemically similar to morphine, oxymorphone, and
codeine and shares many of their analgesic and pharmaco

ference is highly signi?cant from a patient therapy stand

point. When FDA-prescribed bioequivalence statistical meth

provides an unexpected improvement in the intranasal admin
istration of butorphanol.
As will be understood by one of ordinary skill in the art, the
results and conclusions drawn above from the study of the
intranasal administration of butorphanol can be extended in
the practice of the invention to other opioids that can be
administered intranasally in the form of a liquid spray. More
over, the compositions and methods of the present invention
can be practiced to the advantage and bene?t of patients, of
medical facilities and medical professionals, and of society at

30
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HM HCL is a prescription drug narcotic analgesic, more
commonly known by the trade name of DILAUDID® (Merck

40

large for the intranasal administration of other opioids and
controlled substances.
The formulation substantially as described immediately
above was prepared but did not contain benZethonium chlo
ride. This formulation had the following spray pattern func
tion when sprayed from the Pfeiffer Unitdose Second Gen
eration device onto an impaction plate from at various

45

50

1920’s and it has been used in the clinical management of
pain since then. The ?rst extensive literature review was pub
lished in 1933 by the Council on Pharmacy and Chemistry in
the Journal oflheAmerican MedicalAssocialion (Eddy, N. B.

widely accepted in the medical community as a safe and
effective analgesic. It is presently marketed under the trade
name Dilaudid® and Dilaudid-HP by Abbott laboratories.
It is known that HM HCL is subject to hepatic ?rst pass

metabolism when administered orally or by suppository.
Thus, when administered intranasally, the effective unit-dose

maximum diameter (Dmax) of about 2.3 cm (range 2.2-2.4),

55

can be substantially less as compared to doses administered
by oral or rectal routes.

The HM HCL is preferably prepared in the form of a single
or unit-dose nasal spray for intranasal administration by a

precision dosage manually activated pump. Each 1 ml of
60

nasal spray solution is preferably formulated to contain 10 mg
HM hydrochloride with 0.2% sodium chloride, 0.2% sodium
citrate, 0.2% citric acid solution, and sterile water (i.e., water

for injection, USP), accepted antioxidant concentration and
buffer in pharmaceutical products. The pH of this formulation

about 1.1 (range of 1.0 to 1.2; 6.6% RSD).
At a spray distance of 1 cm from a detection laser beam, the
spray has a droplet siZe distribution having a mean Dv10 of
about 15.45 pm (range of 13.70 to 19.98), a mean Dv50 of
about 41.46 pm (range of35.74 to 55.67) and a mean Dv90 of

Index, 1983). Dilaudid (C17Hl9O3NH2O) was discovered by
theA.G. Knoll chemical ?rm of Ludwigshafen, Germany and
was the subject ofa 1923 patent. The ?rst literature describing
the synthesis and testing of this medication appeared in the

Dilaudid (Dihydromorphoninone hydrochloride) J Am Med
Assoc 1933; 100: 1032-1035). The drug is approved and

distances. At a spray distance of 1 cm the spray had an average

an average minimum diameter (DMZ-n) of about 2.1 cm (range
2.0-2.2) and an average ovality of about 1.1 (range of 1.0 to
1.2; 9.1% RSD). At a spray distance of3 cm the spray had an
average maximum diameter (Dmax) of about 5 .2 cm (range of
4.2-6.1), an average minimum diameter (DMZ-n) of about 4.6
cm (range of 3.8-5.8) and an average ovality of about 1.1
(range of 1 .0-1.3; 9.2% RSD).At a spray distance of5 cm, the
spray had an average maximum diameter (Dmax) of about 7.9
cm (range of 7.0-8.4), an average minimum diameter (DMZ-n)
of about 7.2 cm (range of 5.8-8.0) and an average ovality of

logical properties.

was approximately pH 4.0. This formulation was used in the
65

hydromorphone clinical study below.
As will be understood by those familiar with the art, do sage
forms at lower concentrations of hydromorphone can be pre

US 8,198,291 B2
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pared for administration based upon the patient’s lower body

Dilaudid® 4 mg/mL for subjects 2, 4, 5, 6 and 7 on ?rst study
day and for subjects 1, 3, 8 and 9 on the second study day. Free

Weight, as in the case of children or adults of substantially
smaller siZe. The nasal spray solution has a pH in the range of

base content Was 1.77 mg or 88.7% of stated HM HCl

strength (from molecular Weights: 321 .8—36.46:285.34,

from about 3 to about 7, With a pH of about 4-5 being pre
ferred.
In a preferred delivery system, each actuation of the nasal
spray pump delivers 0.1 ml of this 10 mg/ml HM HCL solu
tion constituting a 1 mg dose. A smaller dose may be admin
istered to children. The ?lled applicators can be steriliZed by
methods Well known in the art. The HM HCL nasal spray

285 .34/32 1 .8:88.7%). To summariZe, the dosages for each of
the three routes of administration Were as folloWs.

Treatment A: 2.0 mg intravenous HM HCL
Treatment B: 2.0 mg intramuscular HM HCl; and
Treatment C: 2.0 mg intranasal HM HCl solution

Study Drug Administration
On days 1 and 8, 2.0 mg of HM HCl Was given intrave
nously or intramuscularly in random order folloWing an over

applicators are stored at 15°-30o C. (59°-86o F.) and protected
from light to provide for maximum shelf life. Since the appli
cator body is not transparent, visual inspection of the drug
product for signs of deterioration is not possible and attention
to the expiration date and storage conditions is important.
Any expired product is discarded in the appropriate manner.

night fast. On day 15, 2.0 mg of HM HCI Was given intrana

sally folloWing an overnight fast (except for Water ad lib).
Subjects Were not permitted to recline for 4 hours folloWing

drug administration and remained fasting for 4 hours (until
lunch) on these study days.
Meals and snacks prepared by the University of Kentucky
Hospital Dietetics and Nutrition department Were provided

An analysis of previous Work describing intranasal (IN)
administration of narcotics suggested that HM HCL is highly
likely to have good bioavailability by the IN route in vieW of
its potency and Water solubility. Extensive revieW of hydro
morphone literature did not reveal any comparative IV/IM/IN

20

concentration versus time or pharmacokinetic data. A proto
col Was designed to determine the bio-availability of HM

different study days.
Safety Measures

HCL by the IM and IN routes by comparing the pharmaco
kinetics of intramuscularly administered HM HCL and intra
nasally administered HM HCL to HM HCL administered via
the IV route. Speci?cally, the objectives of this study Were:
(1) to compare the pharmacokinetics of HM via intranasal,
intramuscular, and intravenous administration of a 2 mg dose
of HM HCL; and (2) to evaluate the bioavailability of 2 mg
HM HCL after intranasal, IM and IV routes of administration
using a standard three-period, crossover design.
A formulation of HM HCL for intranasal administration
Was prepared in the form of a liquid composition at a concen
tration of 1.0 mg ofHM HCL in 0.1 L. The composition Was

for each subject. Subjects Were instructed to eat all of their
meals. All subjects received identical meals and snacks on
each of the treatment days, but received different meals on the

25

Weight, blood pressure, and pulse Were measured prior to
dosing and at the end of the study. Blood pressure and pulse
rate Were measured With the subjects seated in an upright

position before any corresponding blood sample Was col
30

lected. Blood pressure and pulse rate Were measured and
recorded on the same arm throughout the study at 0 (pre-do se)

and 30 minutes, 1, 2, 4, 8 and 16 hours.
Clinical Adverse Events
Spontaneously reported adverse events Were recorded by
the subjects throughout the study; adverse events Were also
35

elicited by non-directed intervieWs.

used to ?ll the required number of single-dose, metered

Sample Collection

sprayers commercially produced and sold by Pfeiffer of

Blood samples for period I through period III Were col
lected from each subject according to the folloWing schedule:
0 (pre-dose), 5, 10, 15,20, 30 and 45 minutes, and 1, 2, 3, 4,
6, 8, 12 and 16 hours folloWing HM HCl administration. The

America, Inc. Each subject received a single spray in each
nostril for a total of 2.0 mg. A 2.0 mg dose is preferred as

being Within common, safe and labeled doses prescribed for

40

pain management. Commercially available HM HCL (Dilau

beginning of the IV administration Was considered time Zero.

did® for parental administration from Knoll Pharmaceutical
Company) Was purchased for IlVI/IV administration.

After collection, the blood Was centrifuged in a refrigerated
centrifuge at 40 C. to separate the plasma and the cells and the
plasma Was transferred to polypropylene tubes. The plasma
Was stored at approximately —70° C. at the study site until
shipped to an independent analytical service. The plasma Was
maintained froZen during shipping and upon arrival at the
remote analytical facility, the samples Were stored at approxi

Investigational Methods
Nine healthy male subjects betWeen the ages of 22 and 33

45

years participated in this inpatient study. Study participants
Were selected based on inclusion/exclusion criteria, history

and physical exam, laboratory tests, and other customary
procedures. Subject demographics Were recorded. These
included age range: 22-33 years; height range: 168-188 cm;

50

Weight range: 70.3-95.3 kg; origin: six Caucasian, tWo Asian,
one Native American; all Were non-smokers. All nine of the

subjects completed the study according to the protocol. Each

service in accordance With established protocols. Concentra
tions less than 20 pg/mL Were reported as beloW quantitation

of the subjects received 3 doses of 2 mg of HM HCL on three

separate occasions. No clinically signi?cant protocol viola

55

tions occurred during this study. Because the inclusion crite
ria mentioned abstinence from prescription and non-prescrip
tion drugs prior to and during the study, any medications
taken in the 14 days before the study and during the study
Were noted.

limit (BQL). Samples With concentrations greater than 2,000
pg/mL Were reanalyZed using a dilution so that the assayed
concentration Was Within the range of 20 to 2,000 pg/mL. QC

samples Were also diluted. During the validation, the preci
60

Clinical Trials

Study Drug Formulation: HM HCL for intranasal adminis

tration Was supplied by the University of Kentucky College of

sion Was expressed as the percent coe?icient of variation (%
CV) and the accuracy as the percent difference from the
theoretical (same as relative error).
Pharmacokinetic Methods
Plasma concentration versus time data for HM Were ana

lyZed using non-compartmental pharmacokinetic methods.

Pharmacy. HM HCl for intravenous administration Was sup

plied as Dilaudid® 1 mg/mL for subjects 1, 3, 8, and 9 on the

mately —200 C. until analyZed.
Bioanalytical Methods
LC/MS/ MS Assay for Hydromorphone
The sample analysis Was performed by an independent

65

Maximum plasma concentration (Cmax) and the corre

?rst day and for subjects 2, 4, 5, 6, 7 on the second study day.

sponding sampling time (Tmax) Were identi?ed by observa

HM HCl for intramuscular administration Was supplied as

tion. Concentration versus time data Were plotted on a semi
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logarithmic scale and the terminal log-linear phase Was
identi?ed by visual inspection. The elimination rate constant
(e2) Was determined as the slope of the linear regression for
the terminal log-linear portion of the concentration versus

compared to IN administration. Mean plasma half-lives and
clearance (after correcting for bioavailability) Were similar

time curve. The terminal half-life value (t 1 /2) Was calculated

hydromorphone from the IN formulation is 64%. The range
Was 50% to 81% bioavailability compared to the IV dose. The
apparent bioavailability of the IM hydromorphone HCL Was
about 30% greater than that of the same dose of IV adminis

for all three treatments.
The arithmetic mean value of absolute bioavailability of

as 0.693 divided by e2.
The area under the curve plotting plasma concentration
versus curve (AUC) Was calculated by the trapezoidal rule
and extrapolated to in?nite time. The AUC to the last time

tration. The source of this aberrant phenomenon Was not

found, but unusual distribution phenomena after parenteral
administration have been reported by others Working in this

point (AUCOJm) Was computed by the linear trapeZoidal rule.
Mean plasma concentration Were calculated for graphical
presentation only. Data included in the mean calculation Were
for samples With measurable concentrations draWn Within 5%
of the nominal sampling time.

?eld.
Statistical Evaluation
The pharmacokinetic parameters in Table 4 Were analyZed

Safety Results

to evaluate the effect of routes of administration and to test for

period and sequence effects. The analysis of this pilot data is
considered in tWo parts: the ?rst part considers only the ?rst

Results of the clinical measurement of vital signs and body
Weight exams Were recorded and nasal exams Were per

formed. A revieW of this data failed to reveal any clinically
signi?cant safety concerns. There Were no serious adverse
events and no subjects Were discontinued due to adverse

tWo periods and includes the factors of treatment, sequence
(i.e., a test of carryover effects) and period; the second part
20

effects. Subjects commented that the intensity of the drug

contains all three periods and treatments, but ignores the
effects of sequence and period. The 2-period analysis is noted

effects Were loWer With the IN route compared to the IV or IM

in Table 4 as period 1 vs. 2 and the last column contains the

administrations.

3-period model.

Bioanalytical Results
Hydromorphone in Plasma by LC/MS/MS Results from
the control samples and calibration curves analyZed With the
study samples and the method validation Was reported: The
overall CV, Which re?ects precision Was <7.4% for the QC
samples. The percent recovery ranged from 94.5 to 100, 1%
for QC concentrations 200.0, 500.0, and 1000 Which re?ects
accuracy Was <6% for the QC samples.
Pharmacokinetic Results

25

signi?cant difference procedure and displayed in Table 4. In
light of the fact that there Were no signi?cant period or

sequence effects (using an alpha level of 0.05), and since this
is a pilot project, it is arguable that the above analysis is
30

concentration versus time graphs folloWing IV, IM and IN
doses of 2 mg hydromorphone HCL during the 6 hours after
dose; FIG. 4 is the same data plotted for 16 hours after the
dose. Curves for all subjects for 6 hours after the IN dose

35

TABLE 4
Summag of signi?cance levels from IN 2-period and 3-period model
40 Parameter

Tm“

NS

NS

0.62

NS

.0001

AUCOVOO
tl/2
CL/F

NS
NS
NS
NS

NS
NS
NS
NS

.0001
.0001
NS
.0001

.0001
.0001
NS
.0001

Dose

NS

NS

.0001

.0001

52

NS

NS

NS

NS

0.71

.0001
.0001

50 *All p-values reported as NS are >0.1.

In this study of nine healthy male subjects that received 2
mg hydromorphone HCL by IV, IM and IN routes, compari

listing of individual and mean pharmacokinetic parameters
55

Rapid absorption of hydromorphone HCl Was observed

sons betWeen the IM and IN doses for purposes of bioequiva
lence could not be completed When it Was found that the
hydromorphone concentrations for the IM dose Were mark
edly different as compared to those from the IN doses.

Noncompar‘tmental analysis of the pharmacokinetic data
gave results similar to previous studies With respect to half
60

lives, clearance, rapid distribution into the tissues, and large
apparent distribution volume (Parab et al. 1988; Hill et al.

1991), although comparisons betWeen this study and previous
studies should be done With caution because of differences in

acquiring the blood sample immediately folloWing the IV
infusion Was delayed resulting in the mean Tmax being
affected. As expected, the hydromorphone Cmax and AUCs
Were signi?cantly higher after IM and IV administration

NS

Treatment
(IV vs IM vs IN)

0.32

45 AUCOV,

elimination rate constant Were also recorded; and a complete

after the IM and IN doses. The Tmax values Were approxi
mately 9 and 18 minutes, on average, for the IM and IN doses,
respectively. The mean Tmax for the IV infusion Was not the
?rst blood sample after the end of the infusion for tWo rea
sons. The peak concentration after the IV dose in one subject
Was not at the ?rst blood sample after the end of the IV
infusion, but at the next time point. In the case of Subject 4,

Treatment
IV vs IM

NS*

Cmax (omit

concentrations versus time pro?les for all subjects Were
recorded; the number of time points used to estimate the

for all 9 subjects Was recorded.

Period
(1 vs 2)

outlier)

evaluate the plasma concentration versus time curves of

hydromorphone folloWing single 2.0 mg doses of hydromor
phone HCL by intravenous (IV), intramuscular (IM), and
intranasal (IN) routes. Individual plasma hydromorphone

Sequence
(1 vs 2)

NS

max

appear in FIG. 5 as a graph of hydromorphone concentrations
versus time folloWing IN doses of 2 mg hydromorphone HCl

to 9 subjects.
Non-compartmental pharmacokinetic analysis Was used to

appropriate.
Since the Cmax value for Subject 07 Was beyond 2 standard
deviations of the mean With all measurements included, there
is an objective method for omitting this value for this subject.
Analyses With and Without this outlier gave the same result.

The plasma hydromorphone HCL concentrations and
actual collection times for each of the 9 subjects Was tabulated
and plasma concentration-time curves for each of the 9 sub
jects Were prepared. Mean concentration-time curves of
FIGS. 3 and 4 are representative for most subjects (mean data
tabulation). FIG. 3 is a plot of the mean (n:9) hydromorphone

There are even more signi?cant treatment effects for these
nine outcomes. Post-hoc analyses are based on Fisher’s least

analytical techniques. Hydromorphone HCL is Well absorbed
65

by the nasal route. Intranasal bioavailability Was approxi
mately 64%, on average. Interindividual variation Was

smaller for Cmax and Tmax for the IN route compared to the IV

US 8,198,291 B2
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cyclorphan, ketobemidone, apocodeine, profadol, cyclor
phan, cyprenorphine, dihydromorphine, pholcodine,

and IM routes. Three compartment characteristics Were sug

gested by the tri-phasic concentration versus time curves, but
compartmental analysis Was not performed.
After the short IV infusion, the hydromorphone concentra

hydroxypethidine, fentanyl, sufentanil and alfentanyl.
Clinical testing of each of the above liquid compositions in

one subject. Peak concentrations after the IM dose Were unex

accordance With the method of the invention as practiced in
the hydromorphone HCL clinical test using a Pfeiffer unit

pectedly rapid and precluded the analysis of the data for
showing the bioequivalence of the IM and IN doses, and that

dose applicator produces results comparable to those
obtained in the hydromorphone HCL Work.

analysis Was not pursued.
Phar'macokinetic parameter estimates yielded CVs less

Example 3

tions peaked at the end of the infusion as expected in all but

than 27% for IN parameters except for VSS (CV 46%). Esti

This example described preferred intranasal compositions

mates of Within-subject variability Were smaller than esti
mates for published studies of IV hydromorphone HCL
(Parab et al.; Hill et al.; Vallner et al.). Using a crossover

of the present invention. The opioid can be dissolved in nasal
carrier that includes a diluent, buffer system, antioxidant, one
or more agents to control viscosity, and sWeetener, ?avoring
agent or masking agent. The dosage and volume to be intra

design and standardizing meal times in this study likely
helped to loWer Within-subj ect variability.

nasally administered can be adjusted according to patient

Clearance is similar for all three routes of administration
regardless of route. Variabilities in CL and VSS estimates are
less after the IV dose compared to the IN dose. The reduced

variability is expected since IV dosing avoids betWeen-sub

speci?c parameters (for example, Weight, age, kidney and
liver function, etc.). Preferred agents and ranges of the intra
20

ject variability in absorption and ?rst-pass metabolism.
Adverse events Were less frequent and milder after the IN
dose compared to the IV and IM doses. Assuming a dose
response relationship, this effect believed to be attributable to
the fact that the bioavailability of the IN dose Was less and the

1. Opioid (One or More)

25

peak concentration loWer, so the subjects effectively received
a loWer dose that Was more sloWly absorbed. Nasal irritation
Was not ob served With the exception of a bad taste in the throat

reported by most subjects after the IN dose. In summary,
hydromorphone HCL is Well absorbed by the nasal route With
bioavailability of 64%. Cmax and Tmax Were similar for IM and
IV routes. Clearance is similar regardless of route.
Hydromorphone HCL produced no systemic adverse

nasal compositions are listed beloW and can be selected from
each group.

Hydromorphone HCl
Butorphanol tartrate
Fentanyl Citrate
Methadone HCl
Oxymorphone HCl
Morphine HCl

01-30
01-100
5-200
05-50
01-30
1-40

mg
mg
mcg
mg
mg
mg

30

2. Buffer (One or More-Optional)

events beyond those commonly experienced by injection.
After single IN doses the subjects complained of bitter taste as
the only local administration effect of the formulation. The

35

bitter taste can be masked by the addition of a sWeetener to the
formulation. Detailed nasal examination demonstrated no

pathology of the naso-pharynx after single administration of
the HM HCL formulations.

Sodium citrate
Sodium acetate

0.01-5%
0.01 -5%

Sodium phosphate

0.01-5%

3. Anti-Oxidant (Optional):
40

In a further series of studies, hydromorphone HCL is going
to be administered in accordance With the method of the
invention as described above to larger groups of volunteers

Butylated hydroxytoluene

0.01-5%

selected from the folloWing categories.
4. SWeetener, ?avoring or masking agent (one or more),

1. in good health, ages 18 to 40;

ogamw

. in good health ages 60 to 80;
. patients With rhinitis;

. post-partum breast feeding for milk transfer;

. post-operative pain in Women;
. children and adolescents With cancer;

50

male knee surgery patients; and

. male and female surgical patients.

The results of these studies indicate the, HM HCL is suit
able for use in providing relief from pain in a Wide variety of
settings Without adverse side effects that are any more sig
ni?cant than those reported for the alternate routes of admin

A sugar, such as sucrose

0.l—5%

Aspartame

0.l—5%

Saccharin
An oil, such as Wintergreen, orange

0.l—5%
0.l—5%

Menthol and/or camphor

0.1-5%

5. Viscosity Control (One or More-Optional)
55

istration, and provides the advantages of convenience, and
rapid onset.
Liquid formulations are prepared as fully dissolved solu
tions in a nasal carrier of each of the folloWing systemic

0. l- l 0%

01-10%

60

analgesics: morphine, apomorphine, metopon, oxymor

phone, desomorphine, dihydromorphine, levorphanol, cycla
Zocine, phenaZoeine, levallorphan, 3-hydroxy-N-methyl
tiaorphinan,
levophenacylmorphan,
meaZocine,
norlevorphanol, phenomorphan, nalorphine, nalbuphine,
buprenorphine, pentaZocine, naloxone, naltrexone, diprenor
phine, nalmexone, cyprenorphine, alaZoeine, oxilorphan,

Methylcellulose

Carbopol

6. Diluent
QS With Water or Saline to the Desired Volume
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Having noW generally described the invention, the same
may be more readily understood through the folloWing refer
ence to the folloWing example, Which is provided by Way of
illustration and is not intended to limit the present invention

unless speci?ed.
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5. The pharmaceutical composition of claim 4, Wherein the
buffering agent is selected from the group consisting of
sodium citrate, sodium acetate, sodium phosphate, potassium
phosphate and mixtures thereof.
6. The pharmaceutical composition of claim 5, Wherein the

What is claimed is:

1. An intranasally deliverable pharmaceutical composition
comprising: an effective amount of hydromorphone or a phar

maceutically acceptable salt thereof and a liquid nasal carrier
that is preservative-free, Wherein the pH of the composition is

composition has a pH of about 3 to 5.
7. The pharmaceutical composition of claim 1 or 2,

from about 3 to about 6, and Wherein upon intranasal admin
istration of the composition containing at least 2 mg to about
10 mg of the hydromorphone or the salt thereof, the subject

Wherein the buffering agent is present in the composition in a
total amount of about 0.01% to 3% by Weight.
8. The pharmaceutical composition of claim 1 or 2,
Wherein the liquidnasal carrier comprises an aqueous diluent.
9. The pharmaceutical composition of claim 8, Wherein the
aqueous diluent is selected from the group consisting of

exhibits a Cmax hydromorphone plasma concentration of at
least about 3000 pg/mL.

2. An intranasally deliverable pharmaceutical composition
comprising an effective amount of hydromorphone or a phar

maceutically acceptable salt thereof, and a preservative-free
liquid nasal carrier comprising sodium chloride, citric acid,
and Water, Wherein the pH of the composition is from about 3
to about 6.

3. A method of treating a mammal suffering from pain

comprising intranasally administering to the mammal the
composition of claim 1 or 2.

4. The pharmaceutical composition of claim 1 or 2,
Wherein the liquid nasal carrier comprises a buffering agent.

20

saline, Water, dextrose or combinations thereof.
10. The pharmaceutical composition of claim 1
Wherein the composition has a pH of about 3 to about
11. The pharmaceutical composition of claim 1
Wherein the composition has a pH of about 3 to about
12. The pharmaceutical composition of claim 1
Wherein the composition has a pH of about 4.
*

*

*

*

*

or 2,
5.
or 2,
5.
or 2,

